Tudriqev for Advanced Melanoma: Who Could Benefit?

How does Tudriqev treat advanced melanoma?

Recent WPR coverage of cancer immunotherapy highlighted an advance for people whose melanoma has resisted treatment: an engineered virus delivered directly into tumors. The FDA authorized Tudriqev, also called vusolimogene oderparepvec-wtpg, with nivolumab for adults with advanced melanoma originating in the skin that cannot be surgically removed and has progressed after a PD-1-blocking treatment regimen. The approval occurred on August 6. [WPR interview](https://www.wpr.org/news/wisconsin-doctor-responds-breakthrough-trial-new-cancer-vaccine), [FDA announcement](https://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma).

The treatment uses modified herpes simplex virus type 1. It is engineered to preferentially multiply inside tumors, breaking cancer cells apart and helping the immune system recognize cancer. Nivolumab blocks PD-1, an immune checkpoint that can restrain anticancer activity. Combining these approaches may stimulate an immune response when previous checkpoint treatment has failed, although the biological rationale alone cannot establish how much benefit the virus adds. [FDA explanation of the treatment mechanism](https://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma).

What did the melanoma trial show, and what remains uncertain?

The IGNYTE study enrolled 140 adults with advanced melanoma following progression on prior PD-1-based treatment. The FDA's efficacy analysis included 91 participants who had at least one tumor lesion that was not injected. In this population, 24.2% achieved an objective response, meaning cancer shrinkage met defined assessment criteria. Among responders, the estimated median response duration was 14.1 months. That duration describes how long responses lasted; it does not describe survival for everyone receiving treatment. [FDA efficacy review](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-vusolimogene-oderparepvec-wtpg-combination-nivolumab-melanoma).

IGNYTE had no randomized comparison group, limiting conclusions about the combination's advantage over other options and the contribution of Tudriqev itself. The FDA's regulatory review records substantial methodological concerns, including disagreement between its primary clinical reviewers and officials recommending approval. The required phase 3 IGNYTE-3 trial compares Tudriqev plus nivolumab with physician-selected treatment, with overall survival as its primary endpoint. This makes the accelerated approval a treatment option supported by response data, with important questions about longer-term benefit still awaiting an answer. [FDA regulatory assessment and confirmatory trial requirements](https://www.fda.gov/media/194230/download?attachment=).

What should patients know about treatment and safety?

The recommended initial Tudriqev course consists of eight injections given two weeks apart, with intravenous nivolumab beginning at week three. Clinicians assess which tumors can be injected safely; deeper lesions may require imaging guidance. Common adverse reactions include fatigue, fever, chills, nausea and injection-site reactions. The practical demands include repeated visits, monitoring and care of injection sites between appointments. [FDA prescribing information](https://www.fda.gov/media/194127/download?attachment=).

Warnings include herpes infection or reactivation, accidental exposure of close contacts, bleeding or injury from injections, and immune-mediated inflammation affecting organs. Patients and caregivers need instructions for dressings and avoiding direct exposure to treated sites and contaminated materials. Antiviral medicines can also interfere with the therapy, so medication changes require coordination with the oncology team. Eligibility therefore involves assessing tumor location, previous treatment and individual risks alongside the possible benefit. [FDA safety and interaction information](https://www.fda.gov/media/194127/download?attachment=).